Research programme: farnesyl transferase inhibitors - Schering-PloughAlternative Names: Sch 704742
Latest Information Update: 24 Aug 2009
At a glance
- Originator Schering-Plough
- Class Pyridines
- Mechanism of Action Farnesyltranstransferase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer